EGFR and non-small cell lung carcinoma: Data on DFS based on stage IB, II, or III disease were available in five RCTs (Fig. 2C) and the pooled results suggested a significant improvement in DFS with EGFR-TKIs in stage IB, II and III NSCLC patients, respectively.